A separate study suggested that overexpression of T158M in an Mecp2-null background ameliorated phenotypic severity and may therefore offer a potential therapeutic strategy for Rett syndrome (Lamonica et al. 2017). This evidence concerns the gene MECP2 and atypical Rett syndrome.